Search Results - immunotherapy

133 Results Sort By:
Orthogonal Cytokine Enhanced CAR T Cells Generated Through Gene Editing
Brief Description: The present disclosure provides methods of producing a modified immune cell responsive to orthogonal cytokine signaling and a modified immune cell produced by said method. The present disclosure further provides a modified immune cell responsive to orthogonal cytokine signaling and methods for treating cancer comprising the modified...
Published: 8/21/2025   |   Inventor(s): K. Christopher Garcia, Michael Milone, Qian Zhang
Keywords(s): Cell Therapy, Immunology, Immunoncology, Immunotherapy, Oncology, Platform Technology
Category(s): Technology Classifications > Therapeutics
Engineered Chimeric Antigen Receptor (CAR) Microglia-Like Cells for the Treatment of Neurodegenerative Disorders
Brief Description: Engineered stem cell/monocyte/macrophage/glia for the treatment and prevention of neurodegenerative disorders associated with misfolded proteins or glia dyshomeostasis. The present disclosure provides compositions and methods comprising chimeric antigen receptors (CARs) specific for amyloid beta (Aβ) and/or Tau. In certain...
Published: 8/19/2025   |   Inventor(s): Matias Porras Paniagua, Saar Gill, Frederick Christian Bennett
Keywords(s): Cell Therapy, Immunotherapy, Neurodegenerative Diseases
Category(s): Technology Classifications > Therapeutics
Compositions and methods of chimeric autoantibody receptor T cells expressing extended phospholipase A2 receptor fragments
Brief Description: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an anti-phospholipase A2 receptor (PLA2R) autoantibody-based B cell receptor (BCR), polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells (e.g., T cells) comprising...
Published: 8/19/2025   |   Inventor(s): Aimee Payne, Baomei Wang
Keywords(s): Cell Therapy, Immunotherapy, Nephrology and Urology
Category(s): Technology Classifications > Therapeutics
Controllable stimulation of genetically engineered lymphocytes for the treatment of cancer
Brief Description: The present disclosure provides methods for controllable stimulation of genetically engineered lymphocytes. Compositions and methods of treatment are also provided. Image: Caption: Reference Media Title: Reference Media: Intellectual Property Title: Intellectual Property: Intellectual Property: US 2025/0057883 A1 Docket Number:...
Published: 8/19/2025   |   Inventor(s): Saar Gill
Keywords(s): Cell Therapy, Immunotherapy, Oncology
Category(s): Technology Classifications > Therapeutics
Delivery of sustained local and systemic immunomodulation
Reducing treatment burden with continuous immune activation Background: Current immunotherapy approaches face significant limitations in both delivery and patient experience. Standard treatments rely on either systemic intravenous injections of antibodies or small molecules that require frequent clinic visits, or localized injections that provide...
Published: 6/13/2025   |   Inventor(s): Srinivas Sridhar, Needa Brown, Jennifer Guerriero, Alexander Gottlieb
Keywords(s): biocompatible, Biodegradable, Biomaterials, Cancer, Drug Delivery, Immunoengineering, immunotherapy, implant, Nanomedicine
Category(s): Technology Classifications > 1. Life Science > Therapeutics
Modified Hyaluronic Acid Hydrogels Containing Hyaluronidase for the Time‐Controlled and Targeted Release of anti-CTLA-4 and other Therapeutic Antibodies (UCLA Case No. 2016-526)
UCLA researchers from the Department of Medicine have developed a novel therapeutic platform for the administration of low-dose Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) antibody for cancer immunotherapy that synergizes with conventional PD-1 therapy while sparing systemic autoimmune toxicity. BACKGROUND: Immune checkpoint inhibitor (CPI)...
Published: 7/17/2025   |   Inventor(s): Michael Roth, Airi Harui
Keywords(s): Cancer Immunotherapy, Immunotherapy
Category(s): Platforms > Drug Delivery, Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology
IgA Monoclonal Antibodies as a Prophylactic and Therapeutic Treatment for Dengue Virus Infection
Enables the prevention and treatment of dengue by avoiding the challenge of Antibody Dependent Enhancement. Background: Dengue virus is one of the most widespread vector-borne viral pathogens in the world. Nearly 400 million dengue virus infections occur each year, resulting in approximately 20,000 deaths. In addition, dengue-associated illness comprises...
Published: 8/21/2025   |   Inventor(s): Adam Waickman, Adam Wegman, Jeffrey Currier, Heather Friberg, Michael McCracken, Gregory Gromowski
Keywords(s): antibody, antibody therapy, biologics, biomedical, disease prevention, immunotherapy, monoclonal antibody, Technologies, viral immunology, viral pathogenesis
Category(s): Technology Classifications > Therapeutics and Vaccines, Technology Classifications > Antibodies, Technology Classifications > Healthcare, Campus > Upstate Medical University
A Method for treating TNF-α-driven pathologies via Fn14 inhibition
https://wsu.technologypublisher.com/files/sites/ncs_3618.pdf
Published: 4/30/2025   |   Inventor(s): Salah-uddin Ahmed, Farheen Shaikh
Keywords(s): anti-inflammatory, Immunotherapy, small molecule, Therapeutics
Category(s): Technologies > Health & Well-being > Chemistry
Gene Modifications to Enhance the Function of PSC-Derived T Cells and NK Cells (UCLA Case No. 2023-129)
UCLA researchers in the Department of Medicine have generated novel pluripotent stem cell derived T cells that exhibit improved survival, expansion, and anti-tumor efficacy for use in cell therapy treatments. BACKGROUND: The Food and Drug Administration has approved several chimeric antigen receptor-T (CAR-T) cell therapies since 2017 to combat lymphoma...
Published: 7/31/2025   |   Inventor(s): Christopher Seet
Keywords(s): CAR-T cell therapy, Immunotherapy, pluripotent stem cell (PSC), T-cell engineering
Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Gene Therapy And Editing
Reducing The Adverse Side Effects Of Using Native T-Cells To Destroy Cancer Cells
A Switchable Bispecific T-Cell Nanoengager (sBiTNE) to link T cells with cancer cells that can be reversed if off-tumor toxicity is detected. Problem: Compounds which link native T-cells with the surface antigens found on cancer cells have emerged as an effective treatment for blood malignancies and are currently being developed for solid tumors....
Published: 4/16/2025   |   Inventor(s): Michael Mitchell, Ningqiang Gong
Keywords(s): Bioengineering, Immunology, Immunoncology, Immunotherapy, Oncology, Platform Technology, Protein/Peptide (Non-Antibody), Small Molecule
Category(s): Technology Classifications > Therapeutics
1 2 3 4 5 6 7 8 9 10 ...